Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18757310 | 1.00 | RIPK1 (0.35) | RIPK1TSHRMAPTPDK1PDK2 | |
| SCHEMBL673556 | 0.84 | TSHR (0.44) | RIPK1TSHRMAPTPDK1PDK2 | |
| SCHEMBL20221847 | 0.80 | DPP4 (0.38) | RIPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL18701586 | 0.80 | RIPK1 (0.44) | RIPK1MAPTLMNA | |
| SCHEMBL19075564 | 0.79 | ATM (0.46) | RIPK1LMNA | |
| SCHEMBL19075572 | 0.79 | ATM (0.46) | RIPK1LMNA | |
| SCHEMBL6629964 | 0.76 | ATM (0.41) | TSHRMAPTGAALMNAKDM4E | |
| SCHEMBL20754267 | 0.76 | ATM (0.41) | TSHRMAPTGAALMNAKDM4E | |
| SCHEMBL26053268 | 0.76 | ATM (0.41) | TSHRMAPTGAALMNAKDM4E | |
| SCHEMBL13079209 | 0.75 | NR1H2 (0.42) | TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146546-A1 | Bicyclic and Tricyclic Heteroaromatic Compounds | NEUROGEN CORPORATION | 2008-06-19 | — | — | US | disclosed |
| US-7326709-B2 | Bicyclic and tricyclic heteroaromatic compounds | NEUROGEN CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146546-A1 | Bicyclic and Tricyclic Heteroaromatic Compounds | GABBR1, GABBR2, GABRA4 | RIPK1 4716/4885TSHR 628/4885MAPT 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.